학술논문
ReACT: Overall survival from a randomized phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma.
Document Type
article
Author
Reardon, David A; Schuster, James; Tran, David Dinh; Fink, Karen L; Nabors, Louis B; Li, Gordon; Bota, Daniela Annenelie; Lukas, Rimas Vincas; Desjardins, Annick; Ashby, Lynn Stuart; Duic, J Paul; Mrugala, Maciej M; Werner, Andrea; Hawthorne, Thomas; He, Yi; Green, Jennifer A; Yellin, Michael Jay; Turner, Christopher D; Davis, Thomas A; Sampson, John H
Source
Journal of Clinical Oncology. 33(15_suppl)
Subject
Language